Clinical Trials on Postintensive Care Syndrome in Switzerland

Total 3388 results

Bayer

Completed

Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack (PACIFIC-AMI)

Acute Myocardial Infarction

Spain, Japan, Belgium, United States, Czechia, Hungary, Switzerland, Netherlands, Germany, Austria, Poland, Italy, Sweden, United Kingdom
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

United States, Sweden, Australia, France, Italy, South Africa, Spain, United Kingdom, Germany, Netherlands, Israel, New Zealand, Belgium, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma

Brain Tumors | Central Nervous System Tumors

United States, Canada, Netherlands, Puerto Rico, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study of the Physical and Emotional Needs of Parents Caring for Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia

Leukemia

United States, Canada, Australia, Switzerland, Puerto Rico, Netherlands
GlaxoSmithKline

Active, not recruiting

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM 14)

Multiple Myeloma

United States, Taiwan, Poland, Thailand, Germany, France, Ireland, Greece, Korea, Republic of, United Kingdom, Australia, Italy, India, Argentina, Canada, Spain, Switzerland, Brazil, Mexico
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Cystic Fibrosis

United States, Australia, Canada, Germany, Switzerland, Israel, Netherlands, Belgium, Italy, United Kingdom, France
Novartis Pharmaceuticals
Roche Pharma AG

Completed

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Adenocarcinoma | Carcinoma | Renal Cell | Nephroid Carcinoma | Hypernephroid

Belgium, Italy, Spain, United Kingdom, Germany, Taiwan, Turkey, Egypt, Hong Kong, Russian Federation, Switzerland, Thailand, France, Netherlands, Korea, Republic of, Brazil, United States, Czech Republic, South Africa, Hungary, ...
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer

Lung Cancer

France, Spain, Australia, United States, Sweden, Belgium, Switzerland, Italy, Egypt, South Africa, Israel, Colombia, Morocco, Norway, Greece, Brazil, Poland, Argentina, Austria, Chile, Czech Republic, Former Yugoslavia, Japan, Lithuania, Macedonia, The Former Yugoslav Republic... and more
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

Leukemia

United States, Canada, Australia, Switzerland, New Zealand
Pfizer

Terminated

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Alzheimer Disease

United States, Spain, France, Japan, New Zealand, Belgium, Portugal, Netherlands, Argentina, United Kingdom, Australia, Slovakia, Poland, Chile, Finland, Italy, South Africa, Sweden, Switzerland
Insmed Incorporated

Recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, Argentina, Australia, Belgium, Brazil, Germany, Italy, Japan, Malaysia, Mexico, Philippines, Switzerland, United Kingdom, Serbia, Austria, Denmark
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
Children's Oncology Group
National Cancer Institute (NCI)

Completed

STI571 in Treating Patients With Recurrent Leukemia

Leukemia

United States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
Janssen Research & Development, LLC

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Multiple Myeloma

United States, Korea, Republic of, Czechia, Israel, Switzerland, Belgium, United Kingdom, Japan, Canada, Spain, Sweden, Germany, Australia, Netherlands, France, Argentina, Brazil, Denmark, Greece, Poland, Ireland, Hungary, Portugal, F... and more
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Hepatitis C, Chronic

United States, Austria, Belgium, Canada, France, Germany, Japan, Portugal, Puerto Rico, Spain, Switzerland, United Kingdom
Forest Laboratories

Completed

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia (CAP)

Bacterial Pneumonia

United States, Russian Federation, Bulgaria, Germany, Poland, Romania, Ukraine, Argentina, Austria, Brazil, Estonia, France, Georgia, Hungary, India, Lithuania, Malaysia, Serbia, Slovakia, South Africa, Spain, Switzerland, Thailand
Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Chronic Myelogenous Leukemia

United States, United Kingdom, Hungary, Japan, Saudi Arabia, Australia, Germany, Canada, France, Netherlands, Spain, Lebanon, Turkey, Korea, Republic of, Argentina, Brazil, Bulgaria, Czechia, Israel, Italy, Mexico, Romania, Russian... and more
Bristol-Myers Squibb

Completed

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection (COMMAND-3)

Hepatitis C

Australia, France, Germany, Italy, United Kingdom, United States, Canada, Poland, Austria, Denmark, Israel, Spain, Russian Federation, Switzerland, Argentina, Brazil
AbbVie

Active, not recruiting

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

Cancer | Acute Myeloid Leukemia (AML)

United States, Australia, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Switzerland, Taiwan, United Kingdom
Pfizer

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

ACUTE LYMPHOBLASTIC LEUKEMIA

Italy, Spain, Belgium, Germany, Hungary, Switzerland, Norway, Austria, France, Czechia, Finland, Netherlands, Sweden, Israel, Poland, Greece, Denmark, Slovakia
Bristol-Myers Squibb

Completed

Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

Chronic Myeloid Leukemia | Philadelphia-Positive Myeloid Leukemia

Belgium, Netherlands, Spain, United States, Italy, Canada, France, Germany, Peru, Singapore, United Kingdom, Australia, Sweden, Finland, Israel, Ireland, Denmark, Korea, Republic of, Norway, Austria, South Africa, Switzerland
Abbott

Completed

An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY) (RHAPSODY)

Ankylosing Spondylitis

France, Germany, Greece, Italy, Switzerland, Spain, United Kingdom, Belgium, Austria, Netherlands, Norway, Denmark, Finland, Ireland, Sweden
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

AL Amyloidosis

United States, Germany, Spain, Russian Federation, France, Korea, Republic of, Poland, Israel, Netherlands, Japan, Belgium, Greece, Switzerland, Australia, Austria, Brazil, Canada, China, Czechia, Italy, United Kingdom
GlaxoSmithKline

Completed

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Thrombosis, Venous

Netherlands, Spain, Germany, Italy, Poland, Russian Federation, France, Israel, Estonia, Hungary, Slovakia, Latvia, Greece, Ukraine, Czech Republic, Switzerland, Bulgaria
D-Pharm Ltd.

Terminated

Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke (MACSI)

Acute Ischemic Stroke

Spain, Korea, Republic of, Israel, United States, France, Canada, Brazil, South Africa, Netherlands, Czech Republic, Austria, Germany, Italy, Hungary, Poland, Portugal, Slovakia, Switzerland
Otsuka Pharmaceutical Development & Commercialization...

Completed

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

Congestive Heart Failure

United States, Canada, Netherlands, United Kingdom, France, Spain, Germany, Switzerland, Italy, Brazil, Argentina, Russian Federation, Belgium, Romania, Czech Republic, Norway, Poland, Sweden
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

B-cell Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Korea, Republic of, Australia, Japan, United Kingdom, Italy, Poland, France, Switzerland, Sweden
European Huntington's Disease Network

Completed

REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN) (REGISTRY)

Huntington Disease | Huntington's Disease

Finland, United Kingdom, Austria, Belgium, Czechia, Denmark, France, Germany, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland
Novo Nordisk A/S

Recruiting

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4) (FRONTIER4)

Haemophilia A With Inhibitors | Haemophilia A

Taiwan, Canada, Spain, Netherlands, Korea, Republic of, India, United States, United Kingdom, China, Portugal, Lithuania, Turkey, South Africa, Ireland, Italy, France, Japan, Belgium, Malaysia, Poland, Austria, Bulgaria, Denmark, Germany and more
GlaxoSmithKline

Active, not recruiting

Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Pruritus

United States, France, Spain, Israel, Belgium, Canada, Czechia, Italy, United Kingdom, China, Germany, Mexico, Japan, Brazil, Poland, Russian Federation, Greece, Argentina, Switzerland, Bulgaria
AstraZeneca

Recruiting

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer | Gastroesophageal Junction Cancer

Canada, Spain, United Kingdom, China, France, Italy, Vietnam, Germany, United States, India, Japan, Taiwan, Thailand, Hong Kong, Switzerland, Poland
Gilead Sciences

Terminated

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR-4)

Nonalcoholic Steatohepatitis

United States, Spain, Hong Kong, Canada, Belgium, Australia, Taiwan, India, Japan, Korea, Republic of, Singapore, United Kingdom, Israel, Puerto Rico, France, New Zealand, Germany, Austria, Italy, Mexico, Poland, Switzerland
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis (SPIRIT-H2H)

Psoriatic Arthritis

Belgium, Hungary, Canada, India, Israel, Italy, Australia, Netherlands, United Kingdom, Mexico, Switzerland, South Africa, Poland, Finland, Argentina, France, Germany, Ukraine, Spain, Austria, Denmark, Sweden
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

BAX 855 Continuation

Hemophilia A

United States, Spain, Netherlands, Australia, Czechia, Korea, Republic of, Taiwan, Poland, Bulgaria, United Kingdom, Germany, Turkey, Israel, Malaysia, Ukraine, Russian Federation, Austria, Switzerland, Japan, Hong Kong, Lithuania, Roman... and more
Actelion

Terminated

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment (SELECT)

Chronic Thromboembolic Pulmonary Hypertension

United States, Taiwan, Belgium, Canada, United Kingdom, Korea, Republic of, Turkey, Poland, Austria, Portugal, Spain, Italy, Switzerland, China, Malaysia, Netherlands, Australia, Thailand, Hungary, Brazil, Bulgaria, Czechia, Germany, ... and more
Boehringer Ingelheim

Completed

A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

Lung Diseases, Interstitial

United States, Spain, United Kingdom, Belgium, Australia, Germany, India, Israel, Thailand, China, Japan, Malaysia, France, Austria, Greece, Norway, Netherlands, Switzerland, Chile, Denmark, Finland, Portugal, Argentina, Brazil, Canada, C... and more
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma

United States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
Boehringer Ingelheim

Completed

A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler

Pulmonary Disease, Chronic Obstructive

Israel, Russian Federation, Ukraine, Bulgaria, Czechia, Hungary, Lithuania, Poland, Romania, Slovenia, Switzerland
Novo Nordisk A/S

Active, not recruiting

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4) (REAL4)

Growth Hormone Deficiency in Children

United States, Korea, Republic of, United Kingdom, Canada, Russian Federation, India, Spain, Italy, Algeria, Austria, France, Ireland, Israel, Japan, Latvia, Poland, Serbia, Thailand, Ukraine, Germany, Slovenia, Switzerland
Bristol-Myers Squibb
AbbVie

Completed

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)

Multiple Myeloma

Canada, United States, Israel, Czechia, Switzerland, Greece, Denmark, Portugal, Italy, Germany, Austria, Norway, Puerto Rico, Spain, Sweden, Turkey
Eli Lilly and Company

Active, not recruiting

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma (ANNOUNCE)

Soft Tissue Sarcoma

United States, Spain, France, Korea, Republic of, Taiwan, Japan, Netherlands, Australia, Hungary, Belgium, Italy, Switzerland, Germany, Denmark, Israel, United Kingdom, Canada, Mexico, Russian Federation, Austria, Argentina, Poland, Finlan... and more
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines (REMIX-2)

Chronic Spontaneous Urticaria

United States, India, Malaysia, Taiwan, Poland, United Kingdom, China, Thailand, Switzerland, Germany, Vietnam, Brazil, Russian Federation, Slovakia, Denmark, Canada, South Africa, Austria
Hoffmann-La Roche

Completed

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab (MabCute)

Non-Hodgkin's Lymphoma

Italy, Russian Federation, United Kingdom, Brazil, Ecuador, Germany, Slovenia, Spain, Norway, Switzerland, France, Hungary, Romania, Austria, Albania, Bulgaria, Slovakia, Sweden, Turkey, Argentina, Colombia, Greece, Egypt, Lithuania
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)

Mesothelioma

Brazil, United States, China, Italy, Australia, Belgium, Chile, Colombia, France, Germany, Greece, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, South Africa, Switzerland, Turkey, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
Pfizer

Completed

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib (INTORSECT)

Renal Cell Carcinoma

United States, Australia, Canada, Spain, France, Italy, Korea, Republic of, Denmark, Germany, United Kingdom, Singapore, Netherlands, Austria, Sweden, Chile, Argentina, China, Finland, Hungary, Switzerland
Gilead Sciences

Terminated

(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF (ARTEMIS-IPF)

Idiopathic Pulmonary Fibrosis

Belgium, France, Germany, Israel, Spain, United States, Switzerland, Colombia, Mexico, Italy, Czech Republic, Australia, Canada, Austria, Poland, United Kingdom, Argentina, Netherlands, Peru, Ireland, Brazil, Chile

Clinical Trials on Postintensive Care Syndrome in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations